S&P ASX All Technology

US Dollar vs AUD

Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

Get Started

NRIX Nurix Therapeutics Inc

13.54

-0.41 (-2.94%)

11 May 2024 - Closed

Delayed by 15 minutes

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

null

Nurix Therapeutics (NASDAQ:NRIX)
Historical Stock Chart
From Apr 2024 to May 2024

Click Here for more Nurix Therapeutics Charts.

Nurix Therapeutics (NASDAQ:NRIX)
Historical Stock Chart
From May 2023 to May 2024

Click Here for more Nurix Therapeutics Charts.

Nurix Therapeutics Inc News

Nurix Therapeutics to Participate in RBC Capital Markets Global Healthcare Conference
Tuesday 7 May 2024 (6 days ago) • GlobeNewswire Inc.

Nurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Wednesday 17 April 2024 (4 weeks ago) • GlobeNewswire Inc.

Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering
Friday 12 April 2024 (1 month ago) • GlobeNewswire Inc.

Nurix Therapeutics Announces Proposed Public Offering
Friday 12 April 2024 (1 month ago) • GlobeNewswire Inc.

Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Update
Wednesday 10 April 2024 (1 month ago) • GlobeNewswire Inc.

Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies
Wednesday 10 April 2024 (1 month ago) • GlobeNewswire Inc.

Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6
Tuesday 9 April 2024 (1 month ago) • GlobeNewswire Inc.

Nurix Therapeutics to Participate in Upcoming Investor Conferences
Wednesday 3 April 2024 (1 month ago) • GlobeNewswire Inc.

Nurix Therapeutics Announces Extension of Strategic Collaboration with Gilead Sciences
Tuesday 2 April 2024 (1 month ago) • GlobeNewswire Inc.

Nurix Therapeutics is Part of a Team of International Oncology Experts Selected as Cancer Grand Challenges Awardees to Address Pediatric Cancers Using Targeted Protein Degradation (TPD)
Monday 25 March 2024 (2 months ago) • GlobeNewswire Inc.

Nurix Presents the Discovery and Chemical Structure of First-in-Class CBL-B Inhibitor NX-1607 at the American Chemical Society (ACS) Meeting
Thursday 21 March 2024 (2 months ago) • GlobeNewswire Inc.

Form 8-K - Current report
Monday 11 March 2024 (2 months ago) • Edgar (US Regulatory)

More Nurix Therapeutics Inc News Articles

Australia And New Zealan...

JP Morgan Chase

Australian SE All Ordina...

Verizon Communications

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions